Westwood Holdings Group Inc. Lowers Stock Holdings in Avanos Medical, Inc. (NYSE:AVNS)

Westwood Holdings Group Inc. lessened its holdings in Avanos Medical, Inc. (NYSE:AVNS - Free Report) by 36.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,260,569 shares of the company's stock after selling 730,486 shares during the quarter. Westwood Holdings Group Inc. owned approximately 2.74% of Avanos Medical worth $20,068,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of AVNS. T. Rowe Price Investment Management Inc. increased its holdings in Avanos Medical by 27.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company's stock valued at $47,941,000 after buying an additional 644,267 shares during the last quarter. Tributary Capital Management LLC increased its holdings in Avanos Medical by 38.1% in the fourth quarter. Tributary Capital Management LLC now owns 893,008 shares of the company's stock valued at $14,217,000 after buying an additional 246,379 shares during the last quarter. Brown Advisory Inc. increased its holdings in Avanos Medical by 12.0% in the fourth quarter. Brown Advisory Inc. now owns 1,905,094 shares of the company's stock valued at $30,329,000 after buying an additional 204,218 shares during the last quarter. D. E. Shaw & Co. Inc. increased its holdings in Avanos Medical by 43.1% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 494,627 shares of the company's stock valued at $7,874,000 after buying an additional 148,902 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Avanos Medical by 189.8% in the fourth quarter. JPMorgan Chase & Co. now owns 201,634 shares of the company's stock valued at $3,210,000 after acquiring an additional 132,063 shares in the last quarter. Hedge funds and other institutional investors own 95.17% of the company's stock.

Avanos Medical Stock Performance

NYSE AVNS traded down $0.17 during trading hours on Friday, hitting $12.32. The company had a trading volume of 361,531 shares, compared to its average volume of 361,271. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22. Avanos Medical, Inc. has a 1-year low of $11.84 and a 1-year high of $25.36. The company has a market cap of $569.49 million, a PE ratio of 36.22 and a beta of 1.13. The business has a 50 day moving average of $13.01 and a 200-day moving average of $15.49.

Avanos Medical (NYSE:AVNS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.19 by $0.07. Avanos Medical had a net margin of 2.30% and a return on equity of 4.70%. The company had revenue of $167.50 million during the quarter, compared to the consensus estimate of $161.75 million. During the same quarter in the prior year, the firm posted $0.22 earnings per share. Avanos Medical's revenue for the quarter was up .8% on a year-over-year basis. As a group, equities research analysts expect that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Insider Buying and Selling

In related news, SVP Kerr Holbrook sold 7,000 shares of the firm's stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the transaction, the senior vice president now owns 82,047 shares of the company's stock, valued at $1,251,216.75. This trade represents a 7.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 2.64% of the company's stock.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Avanos Medical from a "hold" rating to a "buy" rating in a research note on Wednesday, March 19th.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.